Showing results (101-110 of 165) with videos related to
Sort By:
Pageof 17
Antimicrobial Agents and Chemotherapy|March 23, 2016
Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection ModelBrian D VanScoy, Michael Trang, Jennifer McCauley, et al.Antimicrobial Agents and Chemotherapy|April 28, 2005
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiBrent M Booker, Patrick F Smith, Alan Forrest, et al.Antimicrobial Agents and Chemotherapy|April 15, 2020
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment <i>In Vitro</i> Infection ModelBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.Antimicrobial Agents and Chemotherapy|November 14, 2012
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearanceJürgen B Bulitta, Olanrewaju O Okusanya, Alan Forrest, et al.Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.Antimicrobial Agents and Chemotherapy|December 14, 2011
Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh modelSharath S Hegde, Olanrewaju O Okusanya, Robert Skinner, et al.Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.Antimicrobial Agents and Chemotherapy|December 7, 2011
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineSujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, et al.Journal of Clinical Pharmacology|August 3, 2013
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumoniaScott A Van Wart, Alan Forrest, Tatiana Khariton, et al.Diagnostic Microbiology and Infectious Disease|January 20, 2009
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococciPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.Pageof 17